- Home
- EMF vs GNFT Comparison
EMF vs GNFT Comparison
Compare EMF & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- GNFT
- Stock Information
- Founded
- EMF 1987
- GNFT 1999
- Country
- EMF United States
- GNFT France
- Employees
- EMF N/A
- GNFT N/A
- Industry
- EMF Finance/Investors Services
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EMF Finance
- GNFT Health Care
- Exchange
- EMF Nasdaq
- GNFT Nasdaq
- Market Cap
- EMF 192.8M
- GNFT 172.2M
- IPO Year
- EMF N/A
- GNFT 2019
- Fundamental
- Price
- EMF $12.00
- GNFT $3.45
- Analyst Decision
- EMF
- GNFT Strong Buy
- Analyst Count
- EMF 0
- GNFT 1
- Target Price
- EMF N/A
- GNFT $13.00
- AVG Volume (30 Days)
- EMF 29.3K
- GNFT 6.9K
- Earning Date
- EMF 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- EMF 6.16%
- GNFT N/A
- EPS Growth
- EMF N/A
- GNFT N/A
- EPS
- EMF N/A
- GNFT 0.47
- Revenue
- EMF N/A
- GNFT $86,225,222.00
- Revenue This Year
- EMF N/A
- GNFT $145.20
- Revenue Next Year
- EMF N/A
- GNFT N/A
- P/E Ratio
- EMF N/A
- GNFT $7.17
- Revenue Growth
- EMF N/A
- GNFT 175.45
- 52 Week Low
- EMF $10.58
- GNFT $3.33
- 52 Week High
- EMF $12.67
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- EMF 43.30
- GNFT 29.90
- Support Level
- EMF $11.71
- GNFT $3.35
- Resistance Level
- EMF $12.29
- GNFT $3.57
- Average True Range (ATR)
- EMF 0.12
- GNFT 0.12
- MACD
- EMF 0.02
- GNFT 0.00
- Stochastic Oscillator
- EMF 50.00
- GNFT 17.27
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.